日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity.

一种用于评估核心针穿刺活检中免疫疗法反应的活体肿瘤碎片平台,同时解决肿瘤异质性带来的挑战。

Ramasubramanian T S, Adstamongkonkul Pichet, Scribano Christina M, Johnson Christin, Caenepeel Sean, Hrycyniak Laura C F, Vedder Lindsey C, Dana Nicholas, Baltes Christian, Browning Victoria, Chen Yuan-I, Dietz Thomas, Flietner Evan, Kaplewski Nicholas, Kellner Anna, Korrer Michael, Liu Chao, Marhefke Nathan, McDonnell Payton, Nasreen Amreen, Pope Victoria, Prasad Abhijeet, Richardson Jordyn, Schneider Sidney, Schultz Mikaela M, Sood Chetan, Sunil Aishwarya, Euw Erika von, Wait Eric, Wargowski Ellen E, Advani Pooja, Broome Barbara, Bruckbauer Antje, Godwin Andrew, Kokabi Nima, Lou Yanyan, Martin Robert C G 2nd, Robaina Mercedes, Toia Giuseppe, Routh Joshua, Friedl Andreas, Eliceiri Kevin, Szulczewski Michael, Johnson Scott, Oliner Jon, Galon Jérôme, Capitini Christian, Mukhopadhyay Debabrata, Taube Janis, Braun David, Gierman Hinco J

Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator.

Rezatapopt(一种小分子激活剂)可恢复 Y220C 突变 p53 的肿瘤抑制功能

Puzio-Kuter Anna M, Xu Lizhong, McBrayer Mary Kate, Dominique Romyr, Li Hongju H, Fahr Bruce J, Brown Alyssa M, Wiebesiek Amy E, Russo Brandon M, Mulligan Chris L, Yang Hong, Battaglia Josh, Robell Kimberly A, Thomas Dafydd H, Huang Kuo-Sen, Solovyov Alexander, Greenbaum Benjamin D, Oliner Jonathan D, Davis Thomas W, Dumble Melissa L, Johnson Melissa L, Xiong Shunbin, Yang Peirong, Lozano Guillermina, Fellous Marc M, Vu Binh T, Schram Alison M, Levine Arnold J, Poyurovsky Masha V

Challenges to Innovation Arising from Current Companion Diagnostic Regulations and Suggestions for Improvements

当前伴随诊断法规对创新带来的挑战及改进建议

Oliner, Kelly S; Shiller, Michelle; Schmid, Peter; Ratcliffe, Marianne J; Schetter, Aaron J; Tsao, Ming-Sound

Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON

在POSEIDON研究中,一线转移性非小细胞肺癌患者接受度伐利尤单抗联合或不联合曲美利木单抗治疗,并接受化疗:根据肿瘤突变负荷评估疗效

Peters, S; Oliner, K S; L'Hernault, A; Ratcliffe, M; Madison, H; Lai, Z; Stewart, R; Mann, H; Lowery, C; Garon, E B; Mok, T; Johnson, M L

A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity.

一种用于评估核心针穿刺活检中免疫疗法反应的活体肿瘤碎片平台,同时解决肿瘤异质性带来的挑战

Ramasubramanian T S, Adstamongkonkul Pichet, Scribano Christina M, Johnson Christin, Caenepeel Sean, Hrycyniak Laura C F, Vedder Lindsey, Dana Nicholas, Baltes Christian, Browning Torey, Chen Yuan-I, Dietz Thomas, Flietner Evan, Kaplewski Nicholas, Kellner Anna, Korrer Michael, Liu Chao, Marhefke Nathan, McDonnell Payton, Nasreen Amreen, Pope Victoria, Prasad Abhijeet, Richardson Jordyn, Schneider Sidney, Schultz Mikaela, Sood Chetan, Sunil Aishwarya, von Euw Erika, Wait Eric, Wargowski Ellen, Advani Pooja, Broome Barbara, Bruckbauer Antje, Godwin Andrew, Kokabi Nima, Martin Robert, Robaina Mercedes, Toia Giuseppe, Routh Joshua, Friedl Andreas, Eliceiri Kevin, Szulczewski Mike, Johnson Scott, Oliner Jon, Galon Jérôme, Capitini Christian, Mukhopadhyay Debabrata, Taube Janis, Braun David, Gierman Hinco J

Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone

针对去势抵抗性前列腺癌的 MET 抑制:利妥木单抗联合米托蒽醌和泼尼松的随机 II 期研究和生物标志物分析

Charles J Ryan, Mark Rosenthal, Siobhan Ng, Joshi Alumkal, Joel Picus, Gwenaëlle Gravis, Karim Fizazi, Frédéric Forget, Jean-Pascal Machiels, Sandy Srinivas, Min Zhu, Rui Tang, Kelly S Oliner, Yizhou Jiang, Elwyn Loh, Sarita Dubey, Winald R Gerritsen

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors

AMG 102 与贝伐单抗或莫特塞尼联合治疗晚期实体瘤患者的 Ib 期研究

Peter J Rosen, Christopher J Sweeney, Dorothy J Park, Darrin M Beaupre, Hongjie Deng, Ian M Leitch, Poornima Shubhakar, Min Zhu, Kelly S Oliner, Abraham Anderson, Lorrin K Yee

Label-free fluorescence lifetime imaging for the assessment of cell viability in living tumor fragments

无标记荧光寿命成像用于评估活体肿瘤碎片中的细胞活力

Jason T Smith, Chao J Liu, Jeannine Degnan, Jonathan N Ouellette, Matthew W Conklin, Anna V Kellner, Christina M Scribano, Laura Hrycyniak, Jonathan D Oliner, Chris Zahm, Eric Wait, Kevin W Eliceiri, John Rafter

Assessing cell viability with dynamic optical coherence microscopy

使用动态光学相干显微镜评估细胞活力

Chao J Liu, Jason T Smith, Yuanbo Wang, Jonathan N Ouellette, Jeremy D Rogers, Jonathan D Oliner, Michael Szulczewski, Eric Wait, William Brown, Adam Wax, Kevin W Eliceiri, John Rafter

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer

肿瘤 RAS/BRAF 状态对帕尼单抗联合 FOLFIRI 一线治疗转移性结直肠癌患者的影响

Karthaus, Meinolf; Hofheinz, Ralf-Dieter; Mineur, Laurent; Letocha, Henry; Greil, Richard; Thaler, Josef; Fernebro, Eva; Oliner, Kelly S; Boedigheimer, Michael; Twomey, Brian; Zhang, Ying; Demonty, Gaston; Köhne, Claus-Henning